Overcoming Receptor Tyrosine Kinase mediated resistance to BRAF Inhibitors in metastatic melanoma, colorectal and lung cancers.
Grant number: 1042980 | Funding period: 2013 - 2017
The drug Vemurafenib results in good responses in melanoma patients. However, patients become resistant to treatment. We have identified specific receptors that can cause Vemurafenib resistance, which can be overcome by combination treatment with drugs to these receptors. We will assess melanoma patient samples for expression of these receptors which will be highly beneficial for selecting combination treatments to prevent drug resistance and ensure better prolonged outcomes.
Related publications (5)
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
Rachel Ramsdale, Robert N Jorissen, Frederic Z Li, Sheren Al-Obaidi, Teresa Ward, Karen E Sheppard, Patricia E Bukczynska, Richard J Young, Samantha E Boyle, Mark Shackleton, Gideon Bollag, Georgina V Long, Eugene Tulchinsky, Helen Rizos, Richard B Pearson, Grant A McArthur, Amardeep S Dhillon, Petranel T Ferrao
Most patients with BRAF-mutant metastatic melanoma display remarkable but incomplete and short-lived responses to inhibitors of th..
Pnenotype switching in melanoma: implications for progression and therapy
Frederic Zhentao Li, Amardeep Singh Dhillon, Robin L Anderson, Grant McArthur, Petranel T Ferrao
Epithelial-mesenchymal transition (EMT) is a key process associated with the progression of epithelial cancers to metastatic disea..
Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma
SQ Wong, A Behren, VJ Mar, K Woods, J Li, C Martin, KE Sheppard, R Wolfe, J Kelly, J Cebon, A Dobrovic, GA McArthur
Melanoma is often caused by mutations due to exposure to ultraviolet radiation. This study reports a recurrent somatic C > T chang..